The first deliveries of the doses are expected in Europe in early 2021, following regulatory approval by the European Medicines Agency (EMA). Regulatory approval is subject to a positive opinion by the EMA's Committee for Medicinal Products for Human Use (CHMP) and the European Commission's decision for conditional marketing authorization. The CHMP meeting is planned for January 6, 2021.

Moderna has received orders for its vaccine candidate from the U.S. (200 million, with the option for an additional 300 million), the European Union (160 million), Japan (50 million), Canada (40 million, with the option for an additional 16 million), Switzerland (7.5 million), the U.K. (7 million), Israel (6 million), and others.

Canada increases order for Moderna's COVID-19 vaccine
The Canadian government has increased its confirmed order of Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, by 20 million doses,...

Moderna's COVID-19 vaccine demonstrates durable immunity in early clinical trial
Moderna published interim data from a National Institutes of Health-led phase I study of its messenger RNA (mRNA)-1273 COVID-19 vaccine on December 3...

Moderna expands COVID-19 vaccine supply agreement with U.K.
Moderna has announced a supply agreement with the U.K. government for an additional 2 million doses of messenger RNA (mRNA)-1273, the company's...

EC secures 80M doses of Moderna COVID-19 vaccine
Moderna has announced that the European Commission (EC) has agreed to secure 80 million doses of its COVID-19 vaccine messenger RNA (mRNA)-1273.

Moderna reports EMA review of COVID-19 vaccine candidate, U.K. supply deal
Moderna said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has initiated a rolling review of the firm's messenger...